The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
Obesity Reviews · 2023
DOI: 10.1111/obr.13553 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Obesity Reviews, 2023. Verfasst von Rishi Jobanputra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Quality of Life, Obesity. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health.
Abstract (Originalsprache)
Weight‐lowering pharmacotherapies provide an option for weight management; however, their effects on physical activity, function, and cardiorespiratory fitness are not fully understood. We conducted a systematic review and meta‐analysis of randomized controlled trials to investigate the effect of licensed weight loss pharmacotherapies on physical activity, physical function, and cardiorespiratory fitness in individuals with obesity. Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate. All 14 trials included a self‐reported measure of physical function, with the pooled findings suggesting an improvement favoring the pharmacotherapy intervention groups (SMD: 0.27; 95% CI: 0.22 to 0.32) and effects generally consistent across different therapies. Results were also consistent when stratified by the two most commonly used measures: The Short‐Form 36‐Item Questionnaire (SF‐36) (0.24; 0.17 to 0.32) and the Impact of Weight on Quality Of Life‐Lite (IWQOL‐Lite) (0.29; 0.23 to 0.35). Meta‐regression confirmed a significant association between pharmacotherapy induced weight loss and improved physical function for IWQOL‐Lite ( p = 0.003). None of the studies reported a physical activity outcome, and only one study reported objectively measured cardiorespiratory fitness. Improvements in self‐reported physical function were observed with weight loss therapy, but the effect on physical activity or objectively measured physical function and fitness could not be determined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diabetes Research Centre, University of Leicester, Leicester, UK.
- National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester, UK.
- Department of Health Sciences, University of Leicester, Leicester, UK.
- Department of Family and Community Medicine, College Of Medicine, King Faisal University, Dammam, Saudi Arabia.
- NIHR Applied Research Collaboration East Midlands, Leicester, UK.
ORCID-Profile: Rishi Jobanputra
Förderung
- Department of Health
Zitieren
APA
Jobanputra, R., Sargeant, J. A., Almaqhawi, A., Ahmad, E., Arsenyadis, F., Webb, D. R., Herring, L. Y., Khunti, K., Davies, M. J., & Yates, T. (2023). The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials. Obesity Reviews. https://doi.org/10.1111/obr.13553
Vancouver
Jobanputra R, Sargeant JA, Almaqhawi A, Ahmad E, Arsenyadis F, Webb DR, et al. The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials. Obesity Reviews. 2023. doi:10.1111/obr.13553
BibTeX
@article{Jobanputra2023,
author = {Jobanputra, Rishi and Sargeant, Jack A and Almaqhawi, Abdullah and Ahmad, Ehtasham and Arsenyadis, Franciskos and Webb, David R and Herring, Louisa Y and Khunti, Kamlesh and Davies, Melanie J and Yates, Thomas},
title = {The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials},
journal = {Obesity Reviews},
year = {2023},
doi = {10.1111/obr.13553}
}
EUVIMED